- N Engl J Med 2022; 387:e12
A 51-year-old man with chronic myeloid leukemia who was receiving treatment with nilotinib presented for follow-up with a report that his hair had turned from gray to its original brown color.
- N Engl J Med 2022; 387:558-561
B-cell maturation antigen (BCMA) was identified as a prognostic marker in multiple myeloma more than two decades ago. Starting in 2014, the first use of BCMA as a treatment target was evaluated in patients with multiple myeloma who received chimeric antigen receptor (CAR) T cells.1,2 Today, a range...
- N Engl J Med 2022; 387:495-505
In this phase 1–2 study involving patients with relapsed or refractory myeloma, a bispecific antibody (teclistamab) that mediates T-cell activation and subsequent lysis of myeloma cells expressing B-cell maturation antigen induced responses in 63% of the patients, including a complete response in nearly 40%.
- N Engl J Med 2022; 387:370-372
Treatment for patients with Hodgkin’s lymphoma is one of the success stories of modern medicine. A once uniformly fatal disorder is now curable, even in an advanced stage, in the great majority of patients. In fact, particularly in limited-stage Hodgkin’s lymphoma, much of the therapeutic focus is on maintaining the...
- N Engl J Med 2022; 387:310-320
The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.
- N Engl J Med 2022; 387:273-274
Treatment for triple-negative breast cancers has always been perceived as a “north face” (an allusion to the fact that the north face of a mountain in the northern hemisphere is usually the most formidable and challenging for mountain climbers), and numerous studies have failed to confirm that particular treatments confer...
- N Engl J Med 2022; 387:199-201
User-fee reauthorization creates new opportunities for the FDA to address issues with its accelerated-approval program, including the lack of evidence of clinical benefit for some products.
- N Engl J Med 2022; 387:217-226
Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone.
- N Engl J Med 2022; 387:261-269
A 34-year-old woman presented with hypercortisolism resulting from a metastatic pancreatic neuroendocrine tumor. Chest CT revealed patchy consolidation with cavitation and tree-in-bud opacities. Management decisions were made.
- N Engl J Med 2022; 387:132-147
In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.
- N Engl J Med 2022; 387:184-186
The authors examine the science behind the induction of objective responses in patients with NSCLC who received adagrasib, an inhibitor of a mutant version of KRAS, which was previously thought to be “undruggable.”
- N Engl J Med 2022; 387:120-131
Adagrasib produced responses in 43% of previously treated patients with non–small-cell lung cancer containing a KRASG12C mutation, with median overall survival of 12.6 months. Regressions of stable brain metastases were noted in one third of evaluable patients. Gastrointestinal toxic effects dominated the adverse events, but fewer than 7%...
- N Engl J Med 2022; 387:180-183
Activating mutations in the KRAS proto-oncogene were identified and characterized more than 40 years ago across several distinct human cancers, including pancreatic and colorectal cancers as well as non–small-cell lung cancer (NSCLC). KRAS somatic alterations are found in approximately 25 to 30% of lung adenocarcinomas and...
- N Engl J Med 2022; 387:75-76
The implications of the results of the DESTINY-Breast04 trial reported by Modi et al.1 in this issue of the Journal are difficult to overstate. Immediately practice-changing, these data show that a human epidermal growth factor receptor 2 (HER2)–directed therapy, trastuzumab deruxtecan, leads to significant and striking...
- N Engl J Med 2022; 387:9-20
More than half of breast cancers express low levels of HER2. In a phase 3 trial, the antibody–drug conjugate trastuzumab deruxtecan resulted in longer survival than the physician’s choice of chemotherapy among patients with HER2-low breast cancer.
- N Engl J Med 2022; 386:2471-2481
A total of 12 pediatric patients with diffuse intrinsic pontine glioma were treated with a direct infusion of an oncolytic virus, followed by radiotherapy. The tumor size was reduced in 9 patients, and disease was stable over a median follow-up of 18 months in 8 patients.
- N Engl J Med 2022; 386:2495-2506
Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has historically been associated with a poor outcome, but survival is improving. The epidemiology, pathology, pathophysiology, diagnosis, and treatment of mantle-cell lymphoma are described.
- N Engl J Med 2022; 386:2523-2525
The overrepresentation of a silent variant in KRAS led investigators to explore whether this mutation was biologically relevant (it was) and could be exploited in a mouse model to treat KRAS-mutant cancer.
- N Engl J Med 2022; 386:2482-2494
A trial involving 523 patients with mantle-cell lymphoma randomly assigned patients to receive bendamustine plus rituximab or these drugs plus ibrutinib. At a median follow-up of 7 years, the median progression-free survival with ibrutinib was nearly 81 months, as compared with 53 months without ibrutinib.
- N Engl J Med 2022; 386:2399-2411
Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.